An observational study in Breast Neoplasms, Breast Reconstruction and Postoperative Complications, sponsored by Zhuliling. Active, not recruiting at 20 sites in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Zhuliling · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,932 studies in Breast Neoplasms with a site in China — 870 open to participants now, 1,067 under way, 210 of them phase 3. Breast Neoplasms · China.
Among the 1,932 studies in Breast Neoplasms with a site in China, this one is the 59th largest by planned enrollment of the 408 observational ones that give a count, is one of 188 that started in 2026, is one of 408 observational ones, reaches primary completion later than 515 of the 1,066 other live ones, and was the 1,878th registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →870 of the 1,932 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Guangxi Medical University · Sites in China
Ages 18–70 · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Healthy volunteers
Fudan University · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18+ · Women only
Guangdong Provincial People's Hospital · Sites in China
Ages 18–75 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,932 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 280 · Phase 2 642 · Phase 3 371 · Phase 4 51
First in 1997; this study’s year is marked. 188 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 184 across 3,237 observational studies indexed under Breast Neoplasms.
Median enrollment 120 across the 1,522 interventional studies, 241 across the 408 observational. Of the 446 that completed or were terminated, 77 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
489 of 1,932 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Zhuliling as lead sponsor.
Zhuliling has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
249 of the studies in Breast Neoplasms with a site in China that are under way reach primary completion within a year, 42 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06954961Phase 3InventisBio Co., LtdA Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | 2026-11-30 |
| NCT06968585Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy | 2026-11-30 |
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT04639986Phase 3Gilead SciencesAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | 2026-12 |
| NCT04290793Phase 3Hebei Medical University Fourth HospitalNeoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | 2026-12-01 |
Add all 249 to your calendar (.ics) → With an account.
Among the 1,932 studies in Breast Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter retrospective observational study will develop and validate a CTA-based quantitative risk score-the DIEP Morphological Deviation Score (DIEP-MDS)-to estimate the risk of flap-related vascular compromise and flap failure in patients undergoing DIEP flap breast reconstruction. The score will quantify the extent to which an individual's perforator anatomy deviates from normative anatomic distributions derived from a reference population of individuals without breast cancer or reconstructive surgery. Specifically, a cohort of randomly selected individuals with available CTA imaging will be used to establish population-level reference distributions for key anatomic features relevant to DIEP perforator morphology, including length, diameter, and muscle thickness. The study will determine whether greater deviation in DIEP morphology, as quantified by the DIEP-MDS, is associated with an increased risk of flap-related vascular compromise and flap failure. The score will be evaluated in an internal surgical cohort and externally validated in an independent multicenter surgical cohort. In addition, the study will pre-specify an analysis to assess whether a dual-pedicle strategy is associated with a lower risk of flap-related vascular compromise compared with a single-pedicle strategy across DIEP-MDS risk strata.
Deep inferior epigastric artery perforator (DIEP) flap breast reconstruction is a cornerstone technique in autologous breast reconstruction after mastectomy. By preserving the rectus abdominis muscle while providing durable soft-tissue replacement, the DIEP flap provides reliable reconstructive volume and favorable aesthetic outcomes. Despite these advantages, the success of DIEP flap breast reconstruction depends critically on achieving and maintaining adequate flap perfusion.
Early postoperative flap-related vascular compromise-including venous congestion, arterial insufficiency, pedicle thrombosis, and pedicle kinking or torsion-may require unplanned surgical takeback and can result in flap failure. These events increase perioperative morbidity, expose patients to additional procedures, prolong hospitalization, and increase health care resource utilization. Preoperative identification of patients at increased risk of flap-related vascular compromise is therefore clinically important for surgical planning, patient counseling, and risk mitigation.
The vascular reliability of DIEP flap is closely related to DIEP perforator morphology, including perforator length, diameter, muscle thickness, and other anatomic features relevant to flap perfusion. Computed tomographic angiography (CTA) has become an integral component of preoperative planning for DIEP flap breast reconstruction and is widely used to map perforator anatomy and guide perforator selection. However, CTA-based assessment remains largely descriptive, with emphasis on anatomic mapping and selection of dominant perforators. Few studies have translated CTA-derived DIEP perforator morphology into a standardized quantitative framework for risk stratification of flap-related vascular compromise and flap failure.
We hypothesized that marked deviation of an individual's perforator anatomy from normative anatomic distributions may increase the technical complexity and unpredictability of flap harvest, intramuscular perforator dissection, and pedicle preparation. This deviation in DIEP morphology may predispose to intraoperative vascular traction, vessel injury, vasospasm, or suboptimal pedicle preparation, thereby potentially increasing the risk of early postoperative flap-related vascular compromise, subsequent unplanned surgical takeback, and flap failure.
In this multicenter retrospective observational study, we will develop a CTA-based quantitative risk score, termed the DIEP Morphological Deviation Score (DIEP-MDS). Using a reference CTA cohort of individuals without breast cancer or reconstructive surgery, we will first establish reference distributions for key anatomic features relevant to DIEP perforator morphology, including length, diameter, and muscle thickness. We will then convert CTA-derived anatomic features into a standardized deviation score that quantifies the extent to which a patient's perforator anatomy differs from these reference distributions. In the internal surgical cohort, the study will assess whether higher DIEP-MDS values are associated with increased risks of flap-related vascular compromise requiring unplanned surgical takeback, as well as flap failure. The score will subsequently be externally validated in an independent multicenter surgical cohort. The study will pre-specify an analysis to assess whether a dual-pedicle strategy is associated with a lower risk of flap-related vascular compromise compared with a single-pedicle strategy across DIEP-MDS risk strata.
Adult women will be included in three cohorts. The reference CTA cohort will include women without breast cancer or reconstructive surgery who underwent abdominal CTA for reasons unrelated to breast reconstruction and will establish reference distributions for key anatomic features relevant to DIEP perforator morphology. The internal surgical cohort will include patients who underwent DIEP flap breast reconstruction at the coordinating center and will evaluate the association between the DIEP Morphological Deviation Score (DIEP-MDS) and flap-related vascular compromise and flap failure. The external multicenter surgical cohort will include patients from external centers for external validation of the DIEP-MDS. Clinical outcomes will be assessed only in the surgical cohorts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Adult women without breast cancer or reconstructive surgery who had available abdominal CTA imaging obtained for reasons unrelated to breast reconstruction. This cohort will be used to establish reference distributions for key anatomic features relevant to DIEP perforator morphology, including length, diameter, and muscle thickness.
Patients who underwent DIEP flap breast reconstruction at the coordinating center and had available preoperative abdominal CTA imaging. This cohort will be used to evaluate whether the CTA-derived DIEP Morphological Deviation Score (DIEP-MDS) is associated with flap-related vascular compromise and flap failure.
Patients who underwent DIEP flap breast reconstruction at participating external centers and had available preoperative abdominal CTA imaging. This cohort will be used to externally validate the DIEP-MDS for estimating the risk of flap-related vascular compromise and flap failure.
Number of Participants With Total DIEP Flap Failure Within 30 Days
Total DIEP flap failure will be assessed as a binary outcome (yes/no) through review of postoperative clinical assessments and reoperation records. Total flap failure is defined as complete and irreversible loss of viability of the reconstructed DIEP flap resulting in complete flap removal. The outcome will be reported as the number and percentage of participants who experience total flap failure.
Time frame: Within 30 days after completion of the index DIEP flap surgery.
Unplanned Surgical Takeback for Flap-Related Vascular Compromise Within 48 Hours
Return to the operating room within 48 hours after completion of the index DIEP flap surgery for exploration or intervention prompted by suspected or confirmed flap-related vascular compromise.
Time frame: Within 48 hours after completion of the index DIEP flap surgery.
Composite Early Flap-Related Vascular Compromise or Flap Failure Within 30 Days
Number and proportion of surgical cohort participants who experience either unplanned surgical takeback for suspected or confirmed flap-related vascular compromise within 48 hours after completion of the index DIEP flap surgery or total flap failure within 30 days after completion of the index DIEP flap surgery.
Time frame: Within 30 days after completion of the index DIEP flap surgery.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.